Investigating Weak Interactions in Pharmaceutical Co - Crystal Systems


Pharmaceutical co-crystallisation is emerging as a possible alternative to polymorphs, salts and solvates in the modification of an active pharmaceutical ingredient (API) during dosage form. It may alter the physico-chemical properties of the API (e.g. melting point and solubility), and also have intellectual property implications. Traditionally, co… (More)